Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20384109 | 0.85 | MAPT (0.37) | SIGMAR1 | |
| SCHEMBL14594807 | 0.76 | SIGMAR1 (0.31) | SIGMAR1 | |
| SCHEMBL27397885 | 0.72 | HRH3 (0.30) | HRH3 | |
| SCHEMBL7466006 | 0.72 | HRH3 (0.42) | SIGMAR1HRH3 | |
| SCHEMBL15428838 | 0.71 | MAPT (0.38) | SIGMAR1 | |
| SCHEMBL8540903 | 0.68 | HRH3 (0.33) | HRH3 | |
| SCHEMBL14627262 | 0.67 | SIGMAR1 (0.46) | SIGMAR1 | |
| SCHEMBL14627265 | 0.64 | ACHE (0.34) | — | |
| SCHEMBL15428912 | 0.64 | — | — | |
| SCHEMBL14071674 | 0.63 | SIGMAR1 (0.39) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171454-A1 | Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-06-19 | — | — | US | disclosed |
| US-8633205-B2 | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140171454-A1 | Substituted Pyrrolo[2,3-d]pyrimidines as Inhibitors of Protein Kinases | PRKDC, DCK, CDK2 | SIGMAR1 4677/4885HRH3 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.